

**A. MARY VILAY, PharmD**  
**Curriculum Vitae**

**ADDRESS**

University of New Mexico  
College of Pharmacy  
2502 Marble Ave NE  
MSC 09 5360  
1 University of New Mexico  
Albuquerque, NM 87131-0001

Telephone: (505) 272-3662  
Fax: (505) 272-6749  
E-mail: mvilay@salud.unm.edu

**LICENSURE**

Feb 2010 – Present	New Mexico Board of Pharmacy, NM, USA Registration Number: RP00007404
July 2000 – Present	Alberta College of Pharmacists, AB, Canada Registration Number: 5835

**EDUCATION**

July 2005 – June 2007	Doctor of Pharmacy Leslie Dan Faculty of Pharmacy University of Toronto, Toronto, ON, Canada
Sept 1996 – Apr 2000	Bachelors of Science in Pharmacy with Distinction Faculty of Pharmacy and Pharmaceutical Sciences University of Alberta, Edmonton, AB, Canada
Sept 1994 – Aug 1996	Pre-Pharmacy Faculty of Science University of Alberta, Edmonton, AB, Canada

**POST GRADUATE TRAINING**

July 2007 – June 2009	Critical Care Nephrology Research Fellowship University of Michigan, College of Pharmacy, Ann Arbor, MI Preceptor: Bruce A. Mueller, Pharm.D., FCCP
-----------------------	---

## PROFESSIONAL POSITIONS

July 2015 – Present	Associate Professor University of New Mexico, College of Pharmacy, Department of Pharmacy Practice and Administrative Sciences Assistant Professor University of New Mexico, School of Medicine, Division of Pediatric Nephrology, Albuquerque, NM
July 2009 – June 2015	Assistant Professor University of New Mexico, College of Pharmacy, Department of Pharmacy Practice and Administrative Sciences, Albuquerque, NM
July 2007 – June 2009	Clinical Instructor University of Michigan, College of Pharmacy, Department of Clinical, Social and Administrative Sciences, Ann Arbor, MI
July 2005 – June 2008	Hospital Pharmacist (Part-time) Foothills Medical Centre, Calgary, AB, Canada
May 2000 – June 2005	Hospital Pharmacist with Clinical Specialty in Renal and Pancreas Transplantation Foothills Medical Centre, Calgary, AB, Canada
Sept 2003 – June 2005	Community Pharmacist (Part-time) Shoppers Drug Mart, Calgary, AB, Canada
May 2003 – May 2007	Exam Assessor Objective Structured Clinical Exam (OSCE); Pharmacist Qualifying Exam Part II Pharmacy Examining Board of Canada, Edmonton and Calgary, AB, Canada

## TEACHING EXPERIENCE

Fall 2020	Co-Instructor of Record (Co-IOR) Pharm 843, Aspects of Patient Care Lab V University of New Mexico, College of Pharmacy
-----------	---

(Teaching Experience continued)

Fall 2020 – present	Instructor (14 contact hours) Pharm 823, Aspects of Patient Care Lab III Topic: Medical history interview, Pharmacist Patient Care Process University of New Mexico, College of Pharmacy
Spring 2020 – present	Instructor (3 contact hours) Pharm 576 Molecular Pharmacology (Graduate Course) Topic: Renal Pharmacology University of New Mexico, College of Pharmacy
Spring 2020 – present	Instructor (0.75 contact hours) Pharm 105, Introduction to Pharmacy Practice and Pharmaceutical Sciences (Undergraduate Course) Topic: Clinical Nephrology Pharmacy Practice University of New Mexico, College of Pharmacy
Spring 2020 – present	Instructor (7 contact hours) Pharm 833, Aspects of Patient Care Lab IV Topics: Clinical laboratory tests and Nephrology Pharmacotherapy University of New Mexico, College of Pharmacy
Spring 2019 – present	Co-Instructor of Record (Co-IOR) Pharm 855, Capstone Course University of New Mexico, College of Pharmacy
Spring 2019 – present	Instructor (2 contact hours) Pharm 850, Integrated Pharmacotherapy VIII Topic: Anemias University of New Mexico, College of Pharmacy
Spring 2019 – present	Instructor (4 Contact hours) Pharm 859, Professional Development V Topic: Continuous Professional Development application exercise University of New Mexico, College of Pharmacy
Spring 2010 – present	Nephrology Module Coordinator & Instructor (11 contact hours) (previously Pharm 739, Pharmacotherapy I – 20 h) (previously Pharm 835, Integrated Pharmacotherapy IV – 11h) Pharm 830, Integrated Pharmacotherapy III University of New Mexico, College of Pharmacy

(Teaching Experience continued)

Fall 2010 – present	Preceptor, 4 <sup>th</sup> year Pharmacy Students Nephrology Rotation Pharm 770, Advanced Pharmacy Practice Experience University of New Mexico, College of Pharmacy (2010-2011: 6 P4 Students, 4 wks each) (2011-2012: 8 P4 Students, 4 wks each) (2012-2013: 8 P4 Students, 4 wks each) (2013-2014: 8 P4 Students, 4 wks each) (2014-2015: 8 P4 Students, 4 wks each) (2015-2016: 8 P4 Students, 4 wks each) (2016-2017: 8 P4 Students, 4 wks each) (2017-2018: 6 P4 students, 4 wks each) (2018-2019: 6 P4 students, 4 wks each) (2019-2020: 6 P4 students, 4 wks each) (2020-2021: 6 P4 students, 4 wks each)
Fall 2010 – present	Preceptor, Pharmacy Practice Residents (PGY1 and PGY2) Nephrology Rotation, University of New Mexico Hospital (2010-2011: 6 Residents, 4 wks each) (2011-2012: 3 Residents, 4 wks each) (2012-2013: 4 Residents, 4 wks each) (2013-2014: 6 Residents, 4 wks each) (2014-2015: 4 Residents, 4 wks each) (2015-2016: 3 Residents, 4 wks each) (2016-2017: 5 Residents, 4 wks each) (2017-2018: 2 Residents, 4 wks each) (2018-2019: 2 Residents, 4 wks each) (2019-2020: 2 Residents, 4 wks and 2 wks) (2020-2021: 1 Resident, 4 wks)
Fall 2010 – present	Instructor (2 contact hours) Pharm 810 Fundamental of Pharmacokinetics and Dosage Forms (previously Pharm 726, Pharmacokinetics and Biopharmaceutics – 2 h) Quantifying Renal Function and Renal Drug Dosing University of New Mexico, College of Pharmacy
Fall 2018 – Fall 2019	Co-Instructor of Record (Co-IOR) Pharm 823, Aspects of Patient Care Lab III University of New Mexico, College of Pharmacy

(Teaching Experience continued)

Spring 2018	Co-Instructor of Record (Co-IOR) Pharm 833, Aspects of Patient Care Lab IV University of New Mexico, College of Pharmacy
Fall 2015 – Fall 2016	Instructor of Record (IOR) Pharm 718L, Pharmaceutical Care Lab III University of New Mexico, College of Pharmacy
Spring 2015	Instructor of Record (IOR) Pharm 739, Pharmacotherapy I University of New Mexico, College of Pharmacy
Spring 2015	Instructor (1 contact hour) Pharm 732, Mechanisms of Drug Action III Clinical Correlation, Diabetes University of New Mexico, College of Pharmacy
Spring 2014	Instructor of Record Pharm 752, Pharmacotherapy III University of New Mexico, College of Pharmacy
Spring 2012 – Spring 2014	Instructor (2 - 4 contact hours) Pharm 752, Pharmacotherapy III Solid Organ Transplant University of New Mexico, College of Pharmacy
Spring 2011 – Spring 2017	Instructor (2 contact hours) Pharm 715, Pathophysiology II Pathophysiology of Chronic Kidney Disease and Acute Kidney Injury University of New Mexico, College of Pharmacy
Spring 2010	Case Based Learning Facilitator (12 contact hours) Pharm 765L, Pharmaceutical Care Lab University of New Mexico, College of Pharmacy
Sept 2008 – Dec 2008	Preceptor, 4 <sup>th</sup> Year Masters of Pharmacy Exchange Student from the Department of Pharmacy and Pharmacology, University of Bath, U.K. (Pharmacy Overseas Placement), Clinical Research University of Michigan, College of Pharmacy

(Teaching Experience continued)

Aug 2008 & Jan 2009	Preceptor, 4 <sup>th</sup> Year Pharmacy Students (Advanced Pharmacy Practice Experiences), Ambulatory Care, Nephrology University of Michigan, College of Pharmacy
Oct 2007 & Nov 2008	Instructor, Pharmacy 431(Therapeutics), Drug Induced Nephrotoxicity University of Michigan, College of Pharmacy

## GRANTS AWARDED

### Completed

**Diuretic/cool dialysate trial (DIDIT).** PI: M. Unruh. **Role: Co-Investigator.** Sponsor: Dialysis Clinic, Inc. Status: Funded

Standardized Patient Assessment of Communications in Pharmacy and Medical Students. PI: J. Nawarskas. **Role: Co-Investigator.** Sponsor: American Association of Colleges of Pharmacy, \$3,621. 06/30/2018 – 06/30/2019

Cardiovascular biomarkers in patients with chronic kidney disease: **PI: A. Mary Vilay.** Sponsor: University of New Mexico Health Science Center Clinical and Translational Science Center/Dialysis Clinic, Inc., \$24,425. 10/01/2016 – 09/30/2017.

Improving kidney function assessments in children with cancer. PI: S. Abraham. **Role: Co Investigator.** Sponsor: University of New Mexico Health Science Center Pediatric Research Committee, \$13,820. 01/01/2013 – 12/31/2015

Biomarkers of Staphylococcus aureus infection in a high risk population. **PIs: P.R. Hall, A.M. Vilay.** Co-Investigators: P. Deming, B. Jakeman, R. Mercier, M. Unruh. Sponsor: University of New Mexico College of Pharmacy, \$5,000. 06/01/2013 – 06/30/2015

Trimethoprim/sulfamethoxazole loss in modeled continuous renal replacement therapy. **PI: A. Mary Vilay.** Sponsor: American Association of Colleges of Pharmacy, \$11,000. 01/17/12 – 01/16/13

Modeled efficacy of three times weekly cefazolin dosing in hemodialysis patients to treat infective endocarditis. PI: Jacob M. Kesner, PharmD Candidate. **Faculty Mentors: A. Mary Vilay, Renee-Claude Mercier.** Sponsor: University of New Mexico College of Pharmacy, \$4000. 05/2012 – 08/2012

Relationship between health literacy and chronic kidney disease outcomes. Co-PI: R. Devraj and M. Borrego. **Role: Co-Investigator.** Sponsor: Southern Illinois University-Edwardsville (SIUE), \$13,400. 1/1/2012 – 12/31/2012

(Grants Awarded – Completed (continued))

Trimethoprim and sulfamethoxazole transmembrane clearance during CRRT. **PI: A. Mary Vilay**. Co-Investigators: Jamie G. Barnhill, Renee C. Mercier, Scott E. Walker, Craig S. Wong. Sponsor: University of New Mexico Health Sciences Center Research Allocation Committee, \$10,000. 7/1/2010 – 6/30/2011.

Pharmacokinetics of Invanz® in critically ill patients receiving continuous venovenous hemodialysis. PI: Bruce A. Mueller. **Co-Is: A. Mary Vilay**, Daryl D. DePestel. Sponsor: Merck, \$134,399. December 2009.  
(Grants Completed continued)

Dalbavancin clearance during intermittent and continuous renal replacement therapy (CRRT): an in-vitro investigation. PI: Bruce A. Mueller. **Co-Is: A. Mary Vilay**, Daryl D. DePestel. Sponsor: Pfizer Inc., \$99,369. May 2008.

## RESEARCH PROJECTS CONDUCTED WITHOUT FORMAL FUNDING

### Completed

Toxic nephropathy: analysis of the National Poison Data System database. **PI: A. Mary Vilay**. Co-Is: Renee C. Mercier, Steven A. Seifert, Craig S. Wong. Supported by NIH NCRR GCRC Grant # 5M01 RR000997.

## GRANTS SUBMITTED

Comparative effectiveness of antihypertensive medications in hemodialysis patients (CREAM). PI: Bruce L. Horowitz. **Role: Co-I**. Sponsor: University of New Mexico Health Science Center Pilot Project Award, \$30,000. (2011) Status: Not Funded.

Hemodialysis frequency and nutrition (HFN) trials. Co-PIs: Kamyar Kalantar-Zadeh and Mark L. Unruh. **Role: Co-I**. Sponsor: NIH-NIDDK-RFA-DK-12-010 \$2,274,272. (2012) Status: Withdrawn.

A collaborative care model involving nephrology pharmacist and primary care providers to manage chronic kidney disease. **PI: A. Mary Vilay**. Sponsor: American Society of Health-System Pharmacists Foundation New Investigator Research Grant, Letter of intent submitted. (2013) Status: Not funded

Circulating inflammatory potential due to uremic toxins in chronic kidney disease. PI: Dhara Shah, PharmD Candidate. **Faculty Mentors: Matt Campen, A. Mary Vilay**. Sponsor: University of New Mexico College of Pharmacy. (2014) Status: Not funded

(Grants Submitted (continued))

Improving kidney function assessments in children with cancer. PI S. Abraham. **Role: Co-Investigator**. Sponsor: American Cancer Society Institutional Research Grant #IRG-92-024 \$30,000. (2012, 2014) Status: Not Funded.

## PATENT APPLICATION

Methods related to continuous renal replacement therapy. Inventors: **Vilay, AM** and Wong CS. Provisional Patent Filed: September 2014. Status: Closed

## PUBLICATIONS

### Peer-reviewed Manuscripts

1. **Vilay AM**, Churchwell MD, Mueller BA. Drug metabolism and non-renal clearance in acute kidney injury. Crit Care 2008; 12: 235. (*on-line journal*) PMID: 19040780
2. Stevenson JM, Patel JH, Churchwell MD, **Vilay AM**, DePestel DD, Sörgel F, Kinzig M, Jakob V, Mueller BA. Ertapenem clearance during modeled continuous renal replacement therapy. Int J Artif Organs 2008; 31: 1027-1034. PMID: 19115194
3. Scott MK, Shah NA, **Vilay AM**, Thomas J, Kraus MA, Mueller BA. Effect of peridialytic oral supplements on nutritional status and quality of life in chronic hemodialysis patients. J Renal Nutr 2009; 19: 145-152. PMID: 19218041
4. **Vilay AM**, Mueller BA, Haines H, Alten JA, Askenazi DA. Treatment of methotrexate intoxication with various modes of continuous extracorporeal therapy and glucarpidase: a case report. Pharmacotherapy 2010; 30: 53e-58e. PMID: 20030480
5. **Vilay AM**, Shah KH, Churchwell MD, Patel JH, DePestel DD, Mueller BA. Modeled dalbavancin transmembrane clearance during intermittent and continuous renal replacement therapies. Blood Purif 2010; 30:37-43. PMID: 20588011
6. **Vilay AM**, Grio M, DePestel DD, Sowinski KM, Gao L, Heung M, Salama NN, Mueller BA. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med 2011; 39: 19-25. PMID: 20890189
7. Harder JL, Heung M, **Vilay AM**, Mueller BA, Segal JH. Case report: carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose. Hemodial Int 2011; 15: 412-415. PMID: 21676154
8. **Vilay AM**, Wong CS, Schrader RM, Mercier RC, Seifert SA. Indicators for serious kidney complications associated with toxic exposures: an analysis of the National Poison Data System. Clin Toxicol (Phila) 2013; 51: 96-105. PMID 23331216
9. Mueller BA, Jasiak KD, Thiel SR, Stevenson JM, **Vilay AM**, Scoville BA, Churchwell MD, Pasko DA, Perkins N. Vibration enhances clearance of solutes with varying molecular weights during in vitro hemodialysis. ASAIO J 2013; 59: 140-144. PMID 23438776



(Peer-reviewed Manuscripts continued)

10. Stevenson JM, Heung M, **Vilay AM**, Eyler RF, Patel C, Mueller BA. In vitro glucose kinetics during continuous renal replacement therapy: implications for caloric balance in critically ill patients. *Int J Artif Organs* 2013; 36: 861-868. PMID: 24366837
11. Eyler RF, **Vilay AM**, Heung M, Pleva M, Sowinski KM, DePestel DD, Sörgel F, Kinzig M, Mueller BA. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. *Antimicrob Agents Chemother* 2014; 58: 1320-1326. PMID: 24323468
12. Dilworth TJ, Leonard SA, **Vilay AM**, Mercier RC. Vancomycin and piperacillin-tazobactam against methicillin-resistant *Staphylococcus aureus* and vancomycin-intermediate *Staphylococcus aureus* in an *in vitro* pharmacokinetic/pharmacodynamics model. *Clin Ther* 2014; 36: 1334-1344. PMID: 25066667
13. Kesner JM, Yardman-Frank JM, Mercier RC, Wong CS, Walker SE, Argyres DP, **Vilay AM**. Trimethoprim and sulfamethoxazole transmembrane clearance during modeled continuous renal replacement therapy. *Blood Purif* 2014; 38: 195-202. PMID: 25531772
14. Yardman-Frank JM, Mercier RC, Wong CS, **Vilay AM**. Iohexol transmembrane clearance during continuous renal replacement therapy. *Blood Purif* 2015; 39: 188-92. PMID: 25765443
15. Devraj R, Borrego M, **Vilay AM**, Gordon EJ, Pailden J, Horowitz B. Relationship between health literacy and kidney function. *Nephrology* 2015; 23: 360-7. PMID: 25661456
16. Eyler RF, Unruh ML, Quinn DK, **Vilay AM**. Drug dosing of psychotherapeutic agents in end-stage renal disease. *Semin Dial* 2015; 28: 417-26. PMID: 25857865
17. Devraj R, Borrego ME, **Vilay AM**, Pailden J, Horowitz B. Awareness, self-management behaviors, health literacy and kidney function relationships in specialty practice. *World J Nephrol* 2018; 7: 41-50. PMID: 29359119
18. **Vilay AM**. Antibiotic dosing in chronic kidney disease and end-stage renal disease: a focus on contemporary challenges. *Advances Chronic Kidney Dis* 2019; 26: 61-71.

#### Other Peer-Reviewed Publications

1. **Vilay AM**. "Contributions to Nephrology. Vol 165: Cardiorenal syndrome in critical care." (Book review). *Ann Pharmacother* 2010; 44: 2044-2045.
2. **Vilay AM**, Depestel DD, Mueller BA. Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. (Letter to the editor response). *Crit Care Med* 2011; 39: 1244-1245.
3. **Vilay AM**, Mueller BA. Intradialytic oral nutritional supplements improve quality of life. (Letter to the editor). *Am J Kidney Dis* 2013; 61:349. PMID 23318013
4. Anemia Review Panel (member of review panel). Anemia Guidelines for Family Practice. 3<sup>rd</sup> ed. Toronto; MUMS Guideline Clearinghouse; 2014.

## Book Chapter

1. Nguyen, T, **Vilay AM**, O'Mara NB, Maxson R. Dialysis. In: Braund R, ed. Renal Medicine and Clinical Pharmacy: Advanced Clinical Pharmacy – Research Development and Practical Applications. Volume 1. Cham, Switzerland. Springer Nature Switzerland AG 2020: 117-130. <https://doi.org/10.1007/978-3-030-37655-0>.
2. **Vilay AM**, Mueller BA. Drug dosing in acute kidney failure and during kidney replacement therapy. In: Jörres A, Ronco C, Kellum JA, eds. Management of acute kidney problems. 1<sup>st</sup> ed. Heidelberg, Germany: Springer Verlag, 2010: 241-252.

## Abstracts/Posters

1. James DE, **Vilay AM**, Chan YK, Dery RE. Rat airway macrophages and lung tissue produce adrenocorticotropin and beta-endorphin; the amounts are increased in allergy. Am J Respir Crit Care Med 2000; 161: A770.

(Abstracts/Posters continued)

2. **Vilay AM**, Stevenson JM, Churchwell MD, Patel JH, DePestel DD, Sörgel F, Kinzig-Schippers M, Mueller BA. Ertapenem transmembrane clearance during modeled continuous hemofiltration. Blood Purif 2008; 26: 172-3. (Abstract #20) Presented at the 13<sup>th</sup> Annual International Conference on Continuous Renal Placement Therapies, San Diego, CA. February 27-March 1, 2008.
3. **Vilay AM**, Stevenson JM, Churchwell MD, Patel JH, DePestel DD, Sörgel F, Kinzig-Schippers M, Mueller BA. Ertapenem transmembrane clearance during modeled continuous hemodialysis. Blood Purif 2008; 26: 173. (Abstract #21) Presented at the 13<sup>th</sup> Annual International Conference on Continuous Renal Placement Therapies, San Diego, CA. February 27-March 1, 2008.
4. **Vilay AM**, Griö M, DePestel DD, Sowinski KM, Gao L, Salama NN, Mueller BA. Daptomycin pharmacokinetics in patients treated with continuous venovenous hemodialysis. J Am Soc Nephrol 2008; 19: 691A (Abstract #SA-PO2581). Presented at the American Society of Nephrology Renal Week, Philadelphia, PA. November 8, 2008.
5. **Vilay AM**, Mueller BA, Lamp KC. Experience with daptomycin for bacteremia in hemodialysis patients. J Am Soc Nephrol 2008; 19: 927A (Abstract #PUB517). Presented at the American Society of Nephrology Renal Week, Philadelphia, PA. November 8, 2008.
6. Macnowski J, Mueller BA, **Vilay AM**, Heung M. Estimating glucose caloric impact of CRRT utilizing regional citrate anticoagulation with ACD-A. Blood Purif 2009; 27: 290. (Abstract #42) Presented at the 14<sup>th</sup> Annual International Conference on Continuous Renal Placement Therapies, San Diego, CA. February 25-28, 2009.
7. Mueller BA, Shah KH, Patel JH, DePestel DD, **Vilay AM**. Dalbavancin transmembrane clearance (CL<sub>tm</sub>) during modeled continuous hemofiltration (CVVH). Blood Purif 2009; 27: 301. (Abstract #65) Presented at the 14<sup>th</sup> Annual International Conference on Continuous Renal Placement Therapies, San Diego, CA. February 25-28, 2009.

(Abstract/Posters continued)

8. Askenazi D, Mueller BA, Haines H, Alten J, **Vilay AM**. Methotrexate clearance during three continuous renal replacement (CRRT) modalities. *Blood Purif* 2009; 27: 302. (Abstract #66) Presented at the 14<sup>th</sup> Annual International Conference on Continuous Renal Placement Therapies, San Diego, CA. February 25-28, 2009.
9. Heung M, Macnowski JP, **Vilay AM**, Mueller BA. Counting calories in the ICU: impact of CRRT utilizing ACD-A based regional citrate anticoagulation. *J Am Soc Nephrol* 2009; 20: 200A. (Abstract #TH-PO378) Presented at the American Society of Nephrology Renal Week, San Diego, CA. October 29, 2009.
10. Harder JL, Heung M, **Vilay AM**, Mueller BA, Segal JH. Hemodialysis and continuous venovenous hemodialysis are effective in carbamazepine intoxication. *J Am Soc Nephrol* 2009; 20: 989A. (Abstract #PUB716) Presented at the American Society of Nephrology Renal Week, San Diego, CA. October 29, 2009.
11. **Vilay AM**, Wong CS, Schrader RM, Mercier RC, Seifert SA. Acute kidney injury related to toxic exposures. *Pediatr Nephrol* 2010; 25: 1832 (Abstract #183) Presented at The 15<sup>th</sup> Congress of the International Pediatric Nephrology Association, New York, NY. August 30, 2010. (*Selected for oral platform presentation.*)
12. Seifert SA, **Vilay AM**, Wong CS, Schrader RM, Mercier RC. Characterization of acute kidney injury in toxic exposures. *Clin Toxicol (Phila)* 2010; 48: 615. Presented at the North American Congress of Clinical Toxicology, Denver, CO. October 7-12, 2010.
13. Eyler RF, **Vilay AM**, Heung M, Pleva M, Sowinski KM, Depestel D, Mueller BA. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. *J Am Soc Nephrol* 2011; 20: 314A. (Abstract #TH-PO879). Presented at the American Society of Nephrology Kidney Week, Philadelphia, PA. November 10, 2011.
14. **Vilay AM**, Kesner JM, Mercier RC, Argyres DP, Walker SE, Wong CS. Sulfamethoxazole and trimethoprim transmembrane clearance during modeled continuous hemofiltration. *J Am Soc Nephrol* 2011; 20: 314A-5A. (Abstract #TH-PO880). Presented at the American Society of Nephrology Renal Week, Philadelphia, PA. November 10, 2011. (Also presented at the University of New Mexico College of Pharmacy Research Day. March 31, 2011)
15. Mohamed AN, Eyler RF, **Vilay AM**, Hueng M, Mueller BA, Sowinski KM. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemofiltration. Presented at the 2012 American Association of Pharmaceutical Scientists Annual Meeting and Exposition; October 14-18, 2012; Chicago, IL. Poster R6370.
16. Mueller BA, Eyler RF, **Vilay AM**, Hueng M, Sowinski KM. Potential of therapeutic drug monitoring of ertapenem and daptomycin using effluent in continuous renal replacement therapy. *J Am Soc Nephrol* 2012; 23: 85A-6A. (Abstract #SA-OR088). Presented at the American Society of Nephrology Kidney Week, San Diego, CA. November 3, 2012.
17. Devraj R, Borrego M, **Vilay M**, Horowitz B. Health Literacy and Chronic Kidney Disease Knowledge. Presented at the 12<sup>th</sup> Annual Institute for Healthcare Advancement Health Literacy Conference, Irvine CA May 8-10, 2013.

(Abstract/Posters continued)

18. **Vilay AM**, Kesner JM, Yardman-Frank JM, Schrader RM, Mercier RC, Argyres DP, Wong CS. Trimethoprim and sulfamethoxazole loss in modeled continuous renal replacement therapy. *Am J Pharm Educ* 2013; 77: 150. Presented at 114<sup>th</sup> Annual Meeting of the American Association of Colleges of Pharmacy, Chicago, IL, July 14, 2013. (Also presented at the University of New Mexico College of Pharmacy Research Day April 11, 2013, and as an encore presentation at the 2013 American College of Clinical Pharmacy Annual Meeting, Albuquerque NM October 13-16, 2013.)
19. Dilworth TJ, Leonard S, **Vilay AM**, Mercier RC. Vancomycin (VAN) and Piperacillin-Tazobactam (PT) against Methicillin-Resistant *Staphylococcus aureus* (MRSA) and VAN-Intermediate *Staphylococcus aureus* (VISA) in an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) Model. 53<sup>rd</sup> Interscience Conference of Antimicrobial Agents and Chemotherapy, September 10-13, 2013. Control Number 2362.
20. Kesner J, Mercier R, Yardman-Frank JM, **Vilay AM**. Modeled efficacy of three times weekly cefazolin dosing in hemodialysis patients to treat infective endocarditis. *Pharmacotherapy* 2013; 33: e281. Presented at the 2013 American College of Clinical Pharmacy Annual Meeting, Albuquerque NM October 13-16, 2013. (Also presented at University of New Mexico College of Pharmacy Research Day. April 11, 2013.)
21. Devraj R, Borrego M, **Vilay AM**, Pailden J, Horowitz B. Relationship between health literacy, knowledge of self-management behaviors, disease awareness, and kidney function I patients with chronic kidney disease. 2013 Boston University Medical Campus Health Literacy Research Conference, Washington DC October 28-29, 2013.
22. **Vilay AM**, Yardman-Frank JM, Mercier RC, Wong CS. Iohexol as a potential marker to assess CRRT dose. *Hemodial Int* 2015; 19: 157. Presented at the 35<sup>th</sup> Annual Dialysis Conference, New Orleans LA February 1-2, 2015.
23. Abraham S, **Vilay M**, Watts K, Joseph C, Wong C. GFR by iohexol plasma versus the updated Schwartz equation and 24-hour urine. Presented at the 1<sup>st</sup> Annual Cancer & the Kidney International Network Conference, Brussels, Belgium April 14-15, 2015. (Also presented at the University of New Mexico Pediatric Research Day, Albuquerque, NM April 15, 2015.)
24. Abraham S, **Vilay M**, Schwartz G, Wong C. Comparing GFR estimating equations, 24-hour urine and measured iohexol GFR in pediatric patients with Cancer. Presented at the 2018 American Society of Pediatric Hematology/Oncology Conference. Pittsburgh, PA, May 2-5, 2018.
25. Takeda MY, Bachyrycz A, Nawarskas JJ, Anderson JR, **Vilay MA**, Dodd MA, Wittstrom KM, Bleske B. A gap between student's perception and ability in opioid overdose education and naloxone use. Presented at the American Association of Colleges of Pharmacy Annual Meeting. Boston, MA, July 21-25, 2018.

## PROFESSIONAL PRESENTATIONS

1. Clinical and humanistic outcomes of peri-dialytic enteral nutrition. University of Michigan, College of Pharmacy Research Seminar. September 11, 2007.

(Professional Presentations continued)

2. Daptomycin pharmacokinetics in continuous venovenous hemodialysis: preliminary results. University of Michigan, College of Pharmacy Research Seminar. October 2, 2007.
3. Overview of chronic kidney disease and preservation therapies. University of Toledo, College of Pharmacy Homecoming Continuing Education Program. Toledo, OH. October 5, 2008.
4. Prescribing in chronic kidney disease. New Mexico Nurse Practitioner Council Annual Conference. Albuquerque, NM. April 21, 2010.
5. Renal drug dosing: the Cockcroft-Gault versus MDRD showdown. University of New Mexico Health Science Center Project ECHO Clinics. February 21 and 23, 2011.
6. Drug induced nephropathy. University of New Mexico Health Science Center Pediatric Residents. March 24, 2011.
7. Drug dosing during dialysis. University of New Mexico College of Pharmacy Staff Brown Bag Lunch. May 25, 2011.
8. Principles of drug dosing in renal disease. University of New Mexico Nephrology Noon Conference. October 31, 2011.
9. How to successfully compete for research grants – the junior investigator’s perspective. University of New Mexico College of Pharmacy Winter Research Retreat. January 10, 2012.
10. Overview of my research at UNM. University of New Mexico College of Pharmacy 3x5x5 Seminar. April 27, 2012.
11. Assisting patients with chronic kidney disease to achieve better outcomes. New Mexico Pharmacists Association 83<sup>rd</sup> Annual Convention. Albuquerque, NM. June 24, 2012.
12. Pharmacokinetics and pharmacodynamics of drug dosing in renal disease. University of New Mexico Nephrology Noon Conference. April 22, 2013.
13. Pharmacist’s Considerations in Anemia Management. 2013 American College of Clinical Pharmacy Annual Meeting. Albuquerque, NM. October 15, 2013.
14. Drug Dosing Principles in Renal Disease. University of New Mexico Nephrology Noon Conference. March 31, 2014.
15. Hepatic and Renal Adverse Effects of Pharmacologic Agents. 2014 New Mexico Nurse Practitioner Council Annual Conference. Albuquerque, NM. April 11, 2014.
16. The “Attraction” of Phosphate Binders in Chronic Kidney Disease. 2014 New Mexico Society of Health-System Pharmacists Balloon Fiesta Symposium. Albuquerque, NM. October 5, 2014.
17. Pharmacy Practice Module, Advanced Learning Series – New Module on Nephrology. India Association of Colleges of Pharmacy and Faculty of Pharmacy M.S. Ramaiah University of Applied Sciences. Bangalore, India. March 18-20, 2015.
18. Chronic Kidney Disease Management for Pharmacists. Kappa Psi (Gamma Rho Chapter) South West Province Spring 2015. Albuquerque, NM. April 18, 2015.

(Professional Presentations continued)

19. Women in Science Technology Engineering and Math (STEM) Panel. 2015 University of New Mexico Shared Knowledge Conference. Albuquerque, NM. April 23, 2015.
20. Pharmacists' Patient Care Process. University of New Mexico College of Pharmacy Preceptor Development Series. Albuquerque, NM. May 30, 2015. (Encore presentation Presbyterian Healthcare Services Pharmacy Department. Albuquerque, NM. August 28, 2015.)
21. Treatment of Hypertension. University of New Mexico Nephrology Noon Conference. Albuquerque, NM. June 8, 2015.
22. Tips on Being a Successful AACP New Investigator Award Recipient. American Association of Colleges of Pharmacy Practice Section Webinar. June 10, 2015.
23. Late Breaker in Nephrology. 2015 American College of Clinical Pharmacy Global Conference on Clinical Pharmacy. San Francisco, CA. October 21, 2015.
24. Do Proton Pump Inhibitors Affect the Kidneys? University of New Mexico Nephrology Noon Conference. Albuquerque, NM. June 13, 2016.
25. Should We Heed the Renal Failure Warnings Associated with Proton Pump Inhibitors? 2016 New Mexico Society of Health-System Pharmacists Balloon Fiesta Symposium. Albuquerque, NM. October 3, 2016.
26. Promoting Student Centered Learning Using Learning Objectives (Developed by the Student). University of New Mexico College of Pharmacy Preceptor Development Series. Albuquerque, NM. November 17, 2016.
27. Use of Low Molecular Weight Heparins in Patients with Chronic Kidney Disease. University of New Mexico Nephrology Noon Conference. Albuquerque, NM. June 19, 2017.
28. Drug Dosing Across the Spectrum of Acute Kidney Injury. National Kidney Foundation Spring Clinical Meeting 2018. Austin, TX. April 11, 2018.
29. What Associations Exist Between Inflammation, Cardiovascular Disease, and Chronic Kidney Disease?" Nephrology Research Symposium 2018. Albuquerque, NM. June 28, 2018.
30. Drug Dosing in CKD and ESRD. University of New Mexico Nephrology Noon Conference. Albuquerque, NM. July 30, 2018.
31. Renal Drug Dosing (CKD and ESRD). University of New Mexico Nephrology Noon Conference. Albuquerque, NM. June 10, 2019.
32. Drug-Induced Nephrotoxicity. University of New Mexico Nephrology Noon Conference. Albuquerque, NM. June 1, 2020.
33. Drug Pharmacokinetics and Pharmacodynamics in Kidney Disease. University of New Mexico Nephrology Noon Conference. Albuquerque, NM. December 21, 2020.
34. Anti-infectives in Kidney Disease – Focus on non-AIN Nephropathies. University of New Mexico Nephrology Noon Conference. Albuquerque, NM. January 4, 2021.

## HONORS & AWARDS

2015	University of New Mexico College of Pharmacy Teacher Appreciation Award, selected by 2 <sup>nd</sup> year pharmacy students
2013	University of New Mexico College of Pharmacy Faculty Preceptor of the Year Teaching Award, selected by 4 <sup>th</sup> year pharmacy students
2013	Sabra Woolley Memorial Award for best oral presentation at 5 <sup>th</sup> Health Literacy Annual Research Conference (HARC), National Academy of Sciences, Washington, D.C. October 28-29, 2013 for: Devraj R, Borrego M, Vilay M, Pailden J, Horowitz B. Relationship between health literacy, knowledge of self-management behaviors, disease awareness, and kidney function in patients with chronic kidney disease.
2008	13 <sup>th</sup> International Conference on Continuous Renal Replacement Therapy New Fellows Travel Grant
2007	Canadian Society of Hospital Pharmacists Ontario Branch PharmD Award
2000	The Carter-Horner Award for Academic Achievement in Pharmaceutical Therapeutics
1999	Burroughs Wellcome Fund Student Research Award
1999	Novopharm Scholarship in Pharmacy for Academic Achievement in Pharmaceutics
1998	Merck Sharp and Dohme Scholarship in Pharmacy for Academic Achievement

## PROFESSIONAL ACTIVITIES

### UNM College of Pharmacy

Mar 2010 – June 2012	Research and Scholarship Committee Member Developed strategies to support and enhance research/scholarship endeavors throughout the College
Sept 2012 – Sept 2013	Advanced Pharmacy Practice Experience Evaluation Working Group Redeveloped the APPE rotation assessment rubric

(Professional Activities UNM COP continued)

Oct 2012 – Dec 2013	Admissions Committee Interviewed candidates and provided assessment to committee members
Oct 2012 – Dec 2013	Web Redesign Committee <ul style="list-style-type: none"><li>• Provided input regarding website design</li><li>• Developed proposal as to how the website should be maintained and updated</li></ul>
Dec 2012 – Feb 2013	Student Portfolio Revision Working Group <ul style="list-style-type: none"><li>• Discussed most effective method to document student</li></ul>
Jan 2014 – Dec 2014	Faculty Development Committee <ul style="list-style-type: none"><li>• Determined faculty professional development needs in teaching, research and service</li></ul>
Jan 2014 – Dec2014	Pharmacy Practice and Administrative Sciences Department Chair Search Committee <ul style="list-style-type: none"><li>• Identified appropriate job posting/advertisement for position</li><li>• Screened applicants and identified highly qualified individuals to interview</li><li>• Developed framework for interview process</li><li>• Actively participated in candidate interviews</li></ul>
Aug 2014 – Dec 2014	Student Pharmacist Research Interest Group Faculty Co-Advisor <ul style="list-style-type: none"><li>• Provided input regarding activities/initiatives</li><li>• Attended student planned events</li></ul>
Aug 2014 – Dec 2015	Drug Information Task Force (Working Group) <ul style="list-style-type: none"><li>• Developed plan to more strongly integrate drug information longitudinally with emphasis on skills development</li></ul>
Jan 2015 – Dec 2015	Student Affairs Committee <ul style="list-style-type: none"><li>• Addressed aspects of student affairs including recruitment, interviews for admissions, student progression, and scholarships and awards</li></ul>
June 2016 – Jan 2017	Pharmaceutical Sciences Faculty Search Committee Member <ul style="list-style-type: none"><li>• Identified appropriate job posting/advertisement for position</li><li>• Screened applicants and identified highly qualified individuals to interview</li><li>• Developed framework for interview process</li><li>• Actively participated in candidate interviews</li></ul>



(Professional Activities UNM COP continued)

July 2016 – May 2018	<p>Capstone OSCE Planning Committee Chair</p> <ul style="list-style-type: none"> <li>• Developed test content and structure</li> <li>• Organized and procured exam resources</li> <li>• Supervised and conducted exam</li> </ul>
Jan 2018 – July 2018	<p>Remediation Taskforce</p> <ul style="list-style-type: none"> <li>• Develop revised PharmD student remediation plan</li> </ul>
May 2020 – July 2020	<p>Curriculum Office Manager Search Committee</p> <ul style="list-style-type: none"> <li>• Identified appropriate job posting/advertisement for position</li> <li>• Screened applicants and identified highly qualified individuals to interview</li> <li>• Developed framework for interview process</li> <li>• Actively participated in candidate interviews</li> </ul>
Jan 2015 – Present (Jan 2018 – Present)	<p>Curriculum and Learning Assessment Committee (Committee Co-Chair)</p> <ul style="list-style-type: none"> <li>• Managed curricular evaluation/continuous quality improvement processes to optimize the effectiveness and efficiency of the professional curriculum while maintaining compliance with ACPE Accreditation Standards</li> </ul>
Feb 2018 – Present	<p>Pharmacy Practice and Administrative Sciences Department Chair Advisory Committee</p> <ul style="list-style-type: none"> <li>• Advise the Department Chair on matters relating to the department of pharmacy practice</li> </ul>
March 2018 – Present	<p>Curriculum Oversight Group</p> <ul style="list-style-type: none"> <li>• Collaborate with key faculty to provide PharmD curriculum oversight</li> </ul>

UNM Health Science Center

Nov 2020 – Present	University of New Mexico Health Science Center Information Technology Advisory Committee
May 2019 – Present	University of New Mexico Hospital Pharmacy Residency Committee
Jan 2020 – Aug 2020	Executive Vice Present for the University of New Mexico Health Science Center Search Advisory Committee

(Professional Activities UNM HSC continued)

October 2015 – June 2017	University of New Mexico Health Science Center Council Member At-Large, Department of Pharmacy Practice and Administrative Sciences
--------------------------	---

National Professional Activities

Sept 2009 – Present	Pharmacotherapy (Impact Factor 2.2) Manuscript Reviewer
Jan 2011 – Present	American Journal of Kidney Diseases (Impact Factor 5.8) Manuscript Reviewer
May 2011 – Present	Journal of Antimicrobial Chemotherapy (Impact Factor 5.4) Manuscript Reviewer
May 2012 – Present	Critical Care Medicine Journal (Impact Factor 6.1) Manuscript Reviewer
Sept 2012 – Present	Clinical Journal of the American Society of Nephrology (Impact Factor 5.3) Manuscript Reviewer
Aug 2013 – Present	Clinical Toxicology (Impact Factor 3.1) Manuscript Reviewer
Jan 2015 – Present	Medicine Manuscript Reviewer
Dec 2012 – Oct 2013 Oct 2014 – Present	American College of Clinical Pharmacy Nephrology PRN Programming Committee Member
Sept 2020 – Present	Advance American Kidney Health Through Optimal Medication Management Pharmacy Kidney Education Standards and Curriculum Development Subgroup Member
Dec 2020 – Present	Oncology and Nephrology Care Ambulatory Care Self-Assessment Program (ACSAP) and American College of Clinical Pharmacy (ACCP) Chapter Reviewer
April 2015	Hemodialysis International Manuscript Reviewer

(National Professional Activities continued)

May 2011	Thrasher Research Fund Research Proposal Reviewer
Apr 2016 – Apr 2017	CRRT Technologies and Implementation Considerations in Renal/Pulmonary Critical Care 2016 – 2018 Critical Care Self-Assessment Program and the American College of Clinical Pharmacy Book Chapter Reviewer
Mar 2014 – Mar 2016	American Association of Colleges of Pharmacy Annual Meeting Abstract Reviewer
Sept 2013 – June 2014	MUMS Health Anemia Guideline Review Panel Member
Oct 2014 – Sept 2016	American College of Clinical Pharmacy Nephrology Practice and Research Network (PRN) Chair-Elect (October 2014 – September 2015) Chair (October 2015 – September 2016)
Oct 2010 – Oct 2014	American College of Clinical Pharmacy Nephrology PRN Communications Committee Member <ul style="list-style-type: none"> <li>Assisted in preparing newsletter biannually/annually</li> </ul>
Oct 2011 – Oct 2013 Oct 2016 – Oct 2017	American College of Clinical Pharmacy Nephrology PRN Nominations Committee Chair <ul style="list-style-type: none"> <li>Coordinated PRN chair election annually</li> </ul>
Aug 2010 – June 2016	American College of Clinical Pharmacy ACCP Online CV Review Service Volunteer Reviewer
Dec 2007 – May 2012	Canadian Society of Hospital Pharmacists – AB Student Mentorship Program Mentor

**TRAINEE MENTORING**

May 2010 – May 2015	Jacob Kesner Student Research Assistant in my laboratory Worked 10-20 h/week during academic months and 30-40 h/week during summer months Current Position: Hospital Clinical Pharmacy Specialist
---------------------	--

(Trainee Mentoring continued)

May 2012 – May 2014	J. Michael Yardman-Frank Student Research Assistant in my laboratory Worked 10-20 h/week during academic months and 30-40 h/week during summer months Current Position: Medical Student
------------------------	---

## **PROFESSIONAL AFFILIATIONS**

July 2006 – Present	American College of Clinical Pharmacy
July 2006 – Present	Canadian Society of Hospital Pharmacists
Jan 2010 – Present	American Association of Colleges of Pharmacy